Cargando…
A Prospective Population Pharmacokinetic Analysis of Sapropterin Dihydrochloride in Infants and Young Children with Phenylketonuria
BACKGROUND AND OBJECTIVES: Untreated phenylketonuria (PKU), a hereditary metabolic disorder caused by a genetic mutation in phenylalanine hydroxylase (PAH), is characterized by elevated blood phenylalanine (Phe) and severe neurologic disease. Sapropterin dihydrochloride, a synthetic preparation of n...
Autores principales: | Qi, Yulan, Mould, Diane R., Zhou, Huiyu, Merilainen, Markus, Musson, Donald G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306193/ https://www.ncbi.nlm.nih.gov/pubmed/25338975 http://dx.doi.org/10.1007/s40262-014-0196-4 |
Ejemplares similares
-
New era in treatment for phenylketonuria: Pharmacologic therapy with sapropterin dihydrochloride
por: Harding, Cary O
Publicado: (2010) -
Longitudinal quality of life analysis in a phenylketonuria cohort provided sapropterin dihydrochloride
por: Douglas, Teresa D, et al.
Publicado: (2013) -
Pretreatment cognitive and neural differences between sapropterin dihydrochloride responders and non-responders with phenylketonuria
por: Hawks, Zoë, et al.
Publicado: (2017) -
Efficacy and safety of sapropterin dihydrochloride in patients with phenylketonuria: A meta‐analysis of randomized controlled trials
por: Qu, Jinghan, et al.
Publicado: (2019) -
First Japanese case of maternal phenylketonuria treated with sapropterin dihydrochloride and the normal growth and development of the child
por: Nyuzuki, Hiromi, et al.
Publicado: (2019)